How long do patients wait? A real-world study on the delays associated with different anticoagulants for elective cardioversion
C Wall, T Jankowski, V Naruka, P Mota - Clinical Medicine, 2019 - ncbi.nlm.nih.gov
Aims A retrospective comparison of the latency between the time of referral and the date of
cardioversion for patients either starting or continuing on different anticoagulants. Methods …
cardioversion for patients either starting or continuing on different anticoagulants. Methods …
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the …
SH Hohnloser, R Cappato, MD Ezekowitz… - EP …, 2016 - academic.oup.com
Aims We compared patient-reported treatment satisfaction and the economic impact of
anticoagulation therapy with rivaroxaban vs. vitamin K antagonists (VKAs) in patients with …
anticoagulation therapy with rivaroxaban vs. vitamin K antagonists (VKAs) in patients with …
[HTML][HTML] Comparing the delay with different anticoagulants before elective electrical cardioversion for atrial fibrillation/flutter
C Wall, T Jankowski, V Naruka, P Mota - Plos one, 2019 - journals.plos.org
Aims To assess the impact of the introduction of direct oral anticoagulants upon the
outcomes from elective electrical cardioversion for atrial fibrillation. Methods This is a …
outcomes from elective electrical cardioversion for atrial fibrillation. Methods This is a …
The safety of a nurse-led day case cardioversion service in the novel oral anticoagulant era: a single centre experience
P Moore, N Lollback, L Slater, P Gould… - Heart, Lung and …, 2015 - heartlungcirc.org
Background: With the advent of newer oral anticoagulants (NOACs) external direct current
cardioversion (EDDCV) has raised the issue of a potential increased risk of stroke or …
cardioversion (EDDCV) has raised the issue of a potential increased risk of stroke or …
[PDF][PDF] A Retrospective Cohort Study to Compare the Efficacy and Safety of the New Direct Oral Anticoagulants versus Warfarin for Elective Cardioversion in Patients …
E Hassan - EC Cardiology, 2018 - ecronicon.net
Objectives: Our research hypothesis was that the use of DOACs instead of Warfarin for
stroke prevention in elective AF cardioversion can reduce the waiting time to cardioversion …
stroke prevention in elective AF cardioversion can reduce the waiting time to cardioversion …
Abstract P126: Can a Structured Quality Improvement Initiative Reduce Elective Cardioversion Patient Waiting Times?
KP Cowie, S Cecchin, K Soon - 2011 - Am Heart Assoc
Background: Current guidelines recommend anticoagulation with a documented
international normalised ratio of 2-3 for 3 weeks prior to an elective cardioversion (ECV). At …
international normalised ratio of 2-3 for 3 weeks prior to an elective cardioversion (ECV). At …
Early versus delayed cardioversion: why should we wait?
KEJ Airaksinen - Expert Review of Cardiovascular Therapy, 2020 - Taylor & Francis
Introduction: Cardioversion (CV) is the essential component of rhythm control strategy for
atrial fibrillation (AF). This review will focus on how the timing of CV affects the efficacy and …
atrial fibrillation (AF). This review will focus on how the timing of CV affects the efficacy and …
Elective Cardioversion in the Era of Novel Oral Anticoagulants–Does a Nurse Administered Verbal Questionnaire for Compliance Negate the Need for Routine …
MK Rowe, N Lollback, L Slater, J Hill, PA Gould… - Heart, Lung and …, 2018 - Elsevier
Background Anticoagulation prior to elective external direct current cardioversion (EDCCV)
is mandatory. The inability to monitor compliance with novel oral anticoagulants (NOACs) …
is mandatory. The inability to monitor compliance with novel oral anticoagulants (NOACs) …
[HTML][HTML] Poor anticoagulation relates to extended access times for cardioversion and is associated with long-term major cardiac and cerebrovascular events
Ö Erküner, R Claessen, R Pisters, G Schulmer… - International Journal of …, 2016 - Elsevier
Background Patients undergoing elective electrical cardioversion (ECV) for atrial fibrillation
have a temporarily increased risk of thromboembolism. Current guidelines recommend …
have a temporarily increased risk of thromboembolism. Current guidelines recommend …
Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin
AS Frederiksen, AE Albertsen, AMS Christesen… - EP …, 2018 - academic.oup.com
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used as
thromboembolic prophylaxis in cardioversion. We examined the waiting time to …
thromboembolic prophylaxis in cardioversion. We examined the waiting time to …